Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines - Wikidata - awgldk - TriplyDB

Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

http://www.wikidata.org/entity/Q58326930

about

Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity.Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.CD4 +CD25 + regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients.Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells.The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.Combination approaches to potentiate immune response after photodynamic therapy for cancer.Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice.Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome.Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson's Disease, Glioma, and Schwannoma.Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference.Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity.Apoptosis as a mechanism of T-regulatory cell homeostasis and suppression.The Janus face of dendritic cells in cancer.Human FOXP3 and cancer.Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?Exosomes: immune properties and potential clinical implementations.The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.Immature dendritic cell-derived exosomes: a promise subcellular vaccine for autoimmunity.Modulation of immunity by antiangiogenic molecules in cancer.Chemoimmunotherapy: reengineering tumor immunity.Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review.Integrating Immunotherapies in Prostate Cancer.Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors.Adoptive Cellular Therapy (ACT) for Cancer Treatment.Therapeutic vaccines for prostate cancer: recent advances and future directions.Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.Cyclophosphamide potentiates the antitumor effect of immunization with injection of immature dendritic cells into irradiated tumor.Immunotherapy of melanoma by GPI-anchored IL-21 tumour vaccine involves down-regulating regulatory T cells in mouse model.Eliciting protective immune responses against murine myeloma challenge in lymphopenia mice through adoptive transfer of tumor antigen-specific lymphocytes and immunization of tumor vaccine secreting mIL-21.Anti-tumour effects of exosomes in combination with cyclophosphamide and polyinosinic-polycytidylic acid.An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models.

P2860

Q26781522-031C73FD-81E4-4AED-AF0A-741171FDE7B9 Q26865532-8F0FF2E1-A635-421C-8ECF-24BD53AAFB9E Q27027093-2D6BFC6B-5B8F-4EF8-A7BA-89F64E42666C Q33502208-69EE078B-0119-439C-8C11-FBB083416B25 Q33871059-674D9962-4574-4E7C-B14D-A893B1DF107F Q34187201-865F2425-C364-4069-ABF5-9330D35F425B Q34624101-D837303B-4B9D-4ED2-BAA1-33A49903551A Q34759603-B678B70B-FE0B-4144-B91B-A99A30871304 Q34898280-86474080-D474-4491-9E80-A26BF157C684 Q35201890-9FBB68C2-C708-41C9-95BE-6053BBEB8AF8 Q35840314-1D035436-1A15-4FAD-9B26-05725F6DE3F5 Q35871559-1A686FA0-B81F-4CF4-AC1F-C674D658EFED Q35889643-50027CE3-23ED-45FB-92BB-A66F23176051 Q36253709-6D852BEF-1152-45F5-8002-2085090E72EC Q36388495-B147970C-7956-45FA-838A-BE52E335EB48 Q36694931-2F4349D6-CC2C-4727-9271-DC4DFD7F5F59 Q36880469-33A0FF87-C7FA-4059-94F2-A465CA1D95BA Q36949870-D98A67E6-E60B-4A13-B57A-C07A5340ECA7 Q37120261-3F63ECBE-9244-401C-81FE-F7370A2110EE Q37270469-1274369C-9496-44AB-8683-639BC5D32F40 Q37287170-69714AD1-4599-4BB4-B68F-C843BDC2AA9A Q37760416-22825713-FA90-4371-99C2-B584510A9CB8 Q37773303-E182AF4C-79CD-4867-973C-E694A5B495A6 Q37822692-E899AABA-8EE4-45D6-A9B0-E06C394E3F05 Q37959968-8DE1A2CA-3DF5-4F2B-91B5-66650D68D004 Q37970682-6EE881D4-6F06-4F53-8ECB-5B57C857DB87 Q38041479-DC384A79-4D62-455E-8831-5AB7E2F97AA9 Q38074154-826C2919-186C-4C96-97B9-7CD35B9958CE Q38079749-2F822A0A-D09A-40F1-B6FA-4F79A3957A73 Q38109551-C72D00C6-4F43-4B67-A16E-A390CA01A3EA Q38567067-80C0CB92-B841-4027-8F45-A1E8B55369BA Q38787052-F56C5E8E-791F-48DD-B977-C0FDFE4587DF Q38848219-54CE7525-DC50-455B-9D2C-B6AD7D659DBE Q38906558-709BE91D-78FE-4715-B544-F8BC9B897A6D Q39472057-1E2130CE-8B95-4813-AAEB-AE06ABCEFB66 Q39594003-10F6532A-031D-4AA2-B9C4-048D5657EAAB Q39665164-F2662506-21B4-4E12-9703-CB4C688A3058 Q39694463-449520BF-1363-4282-A454-84023666BE20 Q39903777-B42B7B4E-AB3A-446C-AC53-6B5AEB265F52 Q39920448-955DDA0C-34A7-4130-9284-F3E8AD7170B2

P2860

Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

http://www.wikidata.org/entity/Q58326930

description

im Februar 2006 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 01 March 2006

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в лютому 2006

@uk

name

Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

@en

Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

@nl

type

label

Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

@en

Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

@nl

prefLabel

Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

@en

Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

@nl

P1433

Q58326930-EC4213FE-FBE9-4BC3-9BD7-16D5F8A4D83F

P1476

Q58326930-2BDEE22C-E1DF-4ED6-B9D7-33FC61A1FA28

P2093

Q58326930-45F6B4DC-F054-4263-8C0F-DA11EA427A42

Q58326930-78C1C6DF-00A5-4B3A-AEDD-20229556DCEE

Q58326930-7B67A3D6-CC7F-4951-82B4-0756395A5C89

Q58326930-A2209EE2-AA18-4D32-944C-FB9DB20F822B

Q58326930-A5020BB4-9DA1-4B94-A6BA-D49C8DEB64D3

Q58326930-B9DB1CD5-D4DE-498A-A28A-465597366078

Q58326930-C198089D-1932-45A5-980C-B08573B5E3E8

Q58326930-D9D1908F-3EAF-4869-B555-56374AB40396

Q58326930-E1EECB3B-97E5-4466-A8BE-22DB398A8834

Q58326930-E2FBDD71-8834-4144-9E00-EA87FD412058

P304

Q58326930-61282387-6481-4B4A-96F9-90C688947DB7

P31

Q58326930-B082A34D-8E0A-4162-919D-1C37199F428B

P356

Q58326930-9319DE13-9360-48B6-B23C-8194D42056AA

P407

Q58326930-6C562482-4E38-4BE7-BFC5-FF21E4290053

P433

Q58326930-C5BB120C-223C-411E-A2ED-959EAD54CBA7

P478

Q58326930-F6C06E4E-67E4-43BB-9A28-976F1E474F82

P50

Q58326930-14471F4C-0547-4DFC-9759-2A9DE3B3C28C

Q58326930-A332457F-5E59-4462-92ED-148F0EDD5B19

P577

Q58326930-08075B99-939E-4668-9227-E60E16590667

P698

Q58326930-4949C68E-B2E2-4905-A340-281AE8D4E412

P356

JIMMUNOL.176.5.2722

P1433

Journal of Immunology

P1476

Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines

@en

P2093

Antoine F Carpentier

http://www.w3.org/2001/XMLSchema#string

Cédric Ménard

http://www.w3.org/2001/XMLSchema#string

François Lemonnier

http://www.w3.org/2001/XMLSchema#string

Guillaume Darrasse-Jèze

http://www.w3.org/2001/XMLSchema#string

Julien Taieb

http://www.w3.org/2001/XMLSchema#string

Magali Terme

http://www.w3.org/2001/XMLSchema#string

Nathalie Chaput

http://www.w3.org/2001/XMLSchema#string

Noël Schartz

http://www.w3.org/2001/XMLSchema#string

Sophie Novault

http://www.w3.org/2001/XMLSchema#string

Stéphan Roux

http://www.w3.org/2001/XMLSchema#string

P304

2722-2729

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.176.5.2722

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

176

http://www.w3.org/2001/XMLSchema#string

P50

Laurence Zitvogel

Francois Ghiringhelli

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16493027

http://www.w3.org/2001/XMLSchema#string